UBS maintained a 'buy' on Reckitt but cut its price target by 5% to £74 after Q4 results showing like-for-like sales up 5.2% and emerging markets growing 17% LFL, which accounted for more than 100% of group growth. The broker forecasts adjusted EPS of 345p for 2026 (around -2% y/y) and Core Reckitt LFL growth of 4.6% for 2026, while flagging risks from weak Europe and the planned deconsolidation of the Essential Home division; UBS nonetheless points to increased brand investment, higher capex and reorganisation as supportive, with the stock trading at c.5,562p and roughly a 20% discount to peers.
Market structure: Reckitt (LSE:RKT, 5,562p) is the primary beneficiary if the strategic pivot (higher brand investment, capex, new org) converts into sustainable organic growth; emerging-market distributors and local producers also benefit from 17% EM LFL growth, while European retailers and lower-margin EH-like categories face margin pressure from elevated promotions. Pricing power is bifurcating—RKT’s OTC and nutrition franchises can command mix-led pricing in EM but European household categories show elasticity that will keep margins subdued near term. Cross-asset: bigger capex and a temporarily lower EPS profile increase short-term equity downside risk and modestly widen RKT credit spreads; FX sensitivity to EM currencies rises meaningfully (track INR/BRL/CNY moves); input-commodity pressure (surfactants/packaging) remains a second-order cost risk.
Risk assessment: Key tail risks are an abrupt EM slowdown or currency shock (10-20% EM FX moves would meaningfully cut reported growth), regulatory action on infant-formula in key markets (China/India) and execution failure of the EH deconsolidation (accounting/tax or transitional-service issues). Timeline: expect market moves in days around management commentary, Q2 as the tactical inflection (3–6 months) when OTC comps ease, and a potential re-rating over 12–24 months if ROIC improves. Hidden dependencies include distributor payment terms, promotional cadence in Europe and the effective tax rate; catalysts include Q1/Q2 trading updates and formal EH deconsolidation milestones.
Trade implications: Tactical long: establish a 2–3% position in RKT (cash) now, scale to 4% on pullbacks >5%, target 30–35% upside to ~7,400p (UBS PT £74) within 12 months; hedge with a 3-month 5% OTM put if entering >3% size. Options: buy a 12-month RKT call spread (Jan 2027 5,600p/7,200p) sized to cap cost while capturing upside if re-rating occurs; pair trade: long RKT vs short UNILEVER (LSE:ULVR) 1:1 to express relative re-rating (ULVR has higher European exposure, lower EM leverage). Rotate 2–4% from defensives with weak top-line momentum into RKT/consumer-health names over the next 3 months.
Contrarian angle: The market is pricing a near-term EPS dip (-~2% in 2026 per UBS) but underweights the potential multiple expansion from a cleaner, higher-investment growth story—if RKT sustains mid-single-digit Core LFL growth and demonstrates ROIC improvement, the current ~20% discount to peers is likely to compress. This is underpinned by a structural benefit: separating EH makes comparables cleaner and could unlock valuation multiple over 12–24 months; counterpoint risk is FCF compression from higher capex that could delay rerating, so monitor quarterly free-cash-flow conversion and effective tax rate closely.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
